Dat	te:	June 24, 2021			
			Ziqi Chen		
sys	tematic a	nalysis of IncRNA		rug targets for coronary artery disease as revealed by	
rela par to t	ated to the ties whos transpare	e content of your e interests may bo ncy and does not i	manuscript. "Related" mea e affected by the content o	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.	
	e following nuscript o		to the author's relationshi	ps/activities/interests as they relate to the <u>current</u>	
to to	the epider dication, o tem #1 be	miology of hyperto even if that medic elow, report all su	ension, you should declare ation is not mentioned in t	defined broadly. For example, if your manuscript perta all relationships with manufacturers of antihypertension the manuscript. d in this manuscript without time limit. For all other ite	ve
			Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial	planning of the work	
1	manuscrip provision medical w processing	t for the present of (e.g., funding, of study materials, riting, article g charges, etc.) mit for this item.	None		
2		contracts from (if not indicated above).	Time frame: past√None	36 months	

3

4

Royalties or licenses

Consulting fees

√\_None

\_√\_\_None

5	Payment or honoraria for	_√None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	√ None	
	testimony		
	testimony		
7	Support for attending	√ None	
′	meetings and/or travel	None	
	,		
8	Patents planned, issued or	_√None	
	pending		
9	Participation on a Data	√None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	√None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	√None	
12	Receipt of equipment,	√None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	_√None	
	financial interests		
		•	

Ρle	ease summarize	the abo	ove confl	ict of in	nterest ir	າ the	e fol	lowing	box
-----	----------------	---------	-----------	-----------	------------	-------	-------	--------	-----

I have no conflicts of interest to declare.	

	TOTAL DISCLOSORE FORM						
Dat	e: June 24, 2021						
Υοι	ır Name:Dawang Zhou						
Ma	nuscript Title:_ Diagnostic biomarkers and potential drug targets for coronary artery disease as revealed by tematic analysis of IncRNA characteristics						
-	nuscript number (if known):						
rela par to t	he interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are ated to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third ties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment cransparency and does not necessarily indicate a bias. If you are in doubt about whether to list a ationship/activity/interest, it is preferable that you do so.						
	e following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> nuscript only.						
to t	The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.						
	tem #1 below, report all support for the work reported in this manuscript without time limit. For all other items, time frame for disclosure is the past 36 months.						
	Name all entities with whom you have this relationship or indicate  Specifications/Comments  (e.g., if payments were made to you or to your institution)						

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	√None	
	manuscript (e.g., funding,		
	provision of study materials, medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_√None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	√_None	
4	Consulting fees	√None	

5	Payment or honoraria for	_√None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	√ None	
	testimony		
	testimony		
7	Support for attending	√ None	
′	meetings and/or travel	None	
	,		
8	Patents planned, issued or	_√None	
	pending		
9	Participation on a Data	√None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	√None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	√None	
12	Receipt of equipment,	√None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	_√None	
	financial interests		
		•	

Ρle	ease summarize	the abo	ove confl	ict of in	nterest ir	າ the	e fol	lowing	box
-----	----------------	---------	-----------	-----------	------------	-------	-------	--------	-----

I have no conflicts of interest to declare.	

Date: June 2	4, 2021
Your Name:	Xiaocong Zhang
• –	Piagnostic biomarkers and potential drug targets for coronary artery disease as revealed by of IncRNA characteristics
Manuscript number	(if known):
related to the conte parties whose inter	Insparency, we ask you to disclose all relationships/activities/interests listed below that are nt of your manuscript. "Related" means any relation with for-profit or not-for-profit third ests may be affected by the content of the manuscript. Disclosure represents a commitment does not necessarily indicate a bias. If you are in doubt about whether to list a

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Time frame: Since the initial√None	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	√None	
3	Royalties or licenses	√_None	
4	Consulting fees	√None	

5	Payment or honoraria for	√ None	
,	lectures, presentations,	None	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	√ None	
Ŭ	testimony	_ \	
	,		
7	Support for attending	√ None	
,	meetings and/or travel	\	
8	Patents planned, issued or	√ None	
	pending	_ \	
9	Participation on a Data	√ None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	√None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid	,	
11	Stock or stock options	√None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
12	services	Alama,	
13	Other financial or non-	None	
	financial interests		

Please summarize the above conflict of interest in the following box:

I have no conflicts of interest to declare.	

Please place an "X" next to the following statement to indicate your agreement:

Da	te: June 24, 2021		
Yo	ur Name:	Qian Wu	
			rug targets for coronary artery disease as revealed by
	stematic analysis of IncRNA		
Ma	anuscript number (if known)	):	
rel pa to	ated to the content of your rties whose interests may b	manuscript. "Related" mea e affected by the content o necessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment of the sound of the manuscript of the manuscript. If you are in doubt about whether to list a so.
	e following questions apply nuscript only.	to the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
to		ension, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.
	item #1 below, report all su e time frame for disclosure i		d in this manuscript without time limit. For all other items
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	√None	
	medical writing, article		
	processing charges, etc.)  No time limit for this item.		
	ivo time minit for tims item.		
		Time frame: past	36 months
2	Grants or contracts from	_√None	
	any entity (if not indicated		
	in item #1 above).	1	

3

4

Royalties or licenses

Consulting fees

√\_None

\_√\_\_None

		ı	
5	Payment or honoraria for	_√None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	√ None	
Ŭ	testimony		
	testimony		
7	Commont for other direct	al Nana	
/	Support for attending	√None	
	meetings and/or travel		
8	Patents planned, issued or	√ None	
	pending		
9	Participation on a Data	√ None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	√ None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	√ None	
11	Stock of Stock options	\None	
10			
12	Receipt of equipment,	VNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	_√None	
	financial interests		

Ρle	ease summarize	the abo	ove confl	ict of i	nterest ir	າ th	e fol	lowing I	box
-----	----------------	---------	-----------	----------	------------	------	-------	----------	-----

I have no conflicts of interest to declare.	

Date: June 24, 2021	
Your Name: Guifu Wu	
Manuscript Title:_ Diagnostic biomarkers and potential	drug targets for coronary artery disease as revealed by
systematic analysis of IncRNA characteristics	
Manuscript number (if known):	
In the interest of transparency, we ask you to disclose all related to the content of your manuscript. "Related" me parties whose interests may be affected by the content to transparency and does not necessarily indicate a bias relationship/activity/interest, it is preferable that you determine the content of the conten	eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment . If you are in doubt about whether to list a
The following questions apply to the author's relationsh manuscript only.	ips/activities/interests as they relate to the <u>current</u>
• • • • • • • • • • • • • • • • • • • •	e <u>defined broadly</u> . For example, if your manuscript pertains e all relationships with manufacturers of antihypertensive the manuscript.
In item #1 below, report all support for the work reports the time frame for disclosure is the past 36 months.	ed in this manuscript without time limit. For all other item
Name all entities with	Specifications/Comments
whom you have this	(e.g., if payments were made to you or to your
relationship or indicate	institution)
none (add rows as	
needed)	
Time frame: Since the initia	al planning of the work

		whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	√None	
3	Royalties or licenses	√_None	
4	Consulting fees	None	

		ı	
5	Payment or honoraria for	_√None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	√ None	
Ŭ	testimony		
	testimony		
7	Commont for other direct	al Nana	
/	Support for attending	√None	
	meetings and/or travel		
8	Patents planned, issued or	√ None	
	pending		
9	Participation on a Data	√ None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	√ None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	√ None	
11	Stock of Stock options	\None	
10			
12	Receipt of equipment,	VNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	_√None	
	financial interests		

Ρle	ease summarize	the abo	ove confl	ict of i	nterest ir	າ th	e fol	lowing I	box
-----	----------------	---------	-----------	----------	------------	------	-------	----------	-----

I have no conflicts of interest to declare.	